scholarly journals Lack of integrin α-chain endoproteolytic cleavage in furin-deficient human colon adenocarcinoma cells LoVo

1996 ◽  
Vol 317 (3) ◽  
pp. 803-809 ◽  
Author(s):  
Maxime LEHMANN ◽  
Véronique RIGOT ◽  
Nabil G. SEIDAH ◽  
Jacques MARVALDI ◽  
Jean-Claude LISSITZKY

In the present report the biosynthesis of the integrin α-chains endowed with constitutive endoproteolytic cleavage was evaluated in LoVo cells where furin, a subtilisin-like convertase involved in post-translational endoproteolytic processing, is not functional. It was found that cell-surface α3, α6 and αv subunits were not processed endoproteolytically into heavy and light chains as they were in HT29-D4 cells, a furin-competent cell line. Complete removal of N-linked oligosaccharides and pulse–chase experiments confirmed that the cleavage of the α6 integrin subunit occurring 45 min after translation in HT29 cells did not take place in LoVo cells. Apart from cleavage deficiency, α6 subunit glycosylation, association with β4 subunits and targeting to the plasma membrane seemed comparable in LoVo and HT29 cells. The pro-α6 and the pro-α3 subunits immunopurified from LoVo cells were highly sensitive to endoproteolysis by recombinant furin. Furin cleavage was calcium dependent and resulted in the conversion of the 140 kDa pro-α6 into a 120 kDa heavy chain. These results suggest strongly that furin is involved in the endoproteolytic processing of cleavable integrin α subunits.

2013 ◽  
Vol 41 (4) ◽  
pp. 425-432 ◽  
Author(s):  
Soojung Jin ◽  
Seung-Geun Yun ◽  
You Na Oh ◽  
Ji-Young Lee ◽  
Hyun-jin Park ◽  
...  

2009 ◽  
Vol 13 (12) ◽  
pp. 1227-1232 ◽  
Author(s):  
Jian-Dong Huang ◽  
Xiong-Jie Jiang ◽  
Xiao-Min Shen ◽  
Qing-Qing Tang

Two novel axial-disubstituted silicon(IV) phthalocyanines (compounds 1 and 2) have been prepared by introducing paracetamol (a common antipyretic analgesic) or its isomer 4-hydroxyphenylacetamide at the axial positions of silicon(IV) phthalocyanine, respectively. Their photophysical and biological properties have been examined. Both compounds are highly soluble and exhibit very similar absorption spectra in N, N-dimethylformamide, which is typical for non-aggregated phthalocyanines. Both compounds are photocytotoxic against HT29 human colon adenocarcinoma cells. Compound 2 shows a very high in vitro photodynamic activity, with the IC50 value down to 15 nM. In contrast, compound 1 exhibits a much lower in vitro photodynamic activity toward HT29 cells, which can be attributed to its higher aggregating trend in the biological medium and lower singlet oxygen quantum yield.


1990 ◽  
Vol 268 (2) ◽  
pp. 465-470 ◽  
Author(s):  
C Denis-Pouxviel ◽  
T Gauthier ◽  
D Daviaud ◽  
J C Murat

Kinetic properties of phosphofructokinase 2 (PFK2) and regulation of glycolysis by phorbol 12-myristate 13-acetate (PMA) and insulin were investigated in highly glycolytic HT29 colon cancer cells. PFK2 was found to be inhibited by citrate and, to a lesser extent, by phosphoenolpyruvate and ADP, but to be insensitive to inhibition by sn-glycerol phosphate. From these kinetic data, PFK2 from HT29 cells appears different from the liver form, but resembles somewhat the heart isoenzyme. Fructose 2,6-bisphosphate (Fru-2,6-P2) levels, glucose consumption and lactate production are increased in a dose-dependent manner in HT29 cells treated with PMA or insulin. The increase in Fru-2,6-P2 can be related to an increase in the Vmax. of PFK2, persisting after the enzyme has been precipitated with poly(ethylene glycol), without change in the Km for fructose 6-phosphate. The most striking effects of PMA and insulin on Fru-2,6-P2 production are observed after long-term treatment (24 h) and are abolished by actinomycin, cycloheximide and puromycin, suggesting that protein synthesis is involved. Furthermore, the effects of insulin and PMA on glucose consumption, lactate production, Fru-2,6-P2 levels and PFK2 activity are additive, and the effect of insulin on Fru-2,6-P2 production is not altered by pre-treatment of the cells with the phorbol ester. This suggests that these effects are exerted by separate mechanisms.


2015 ◽  
Vol 25 (5) ◽  
pp. 515-522 ◽  
Author(s):  
You Na Oh ◽  
Soojung Jin ◽  
Hyun-jin Park ◽  
Byung Woo Kim ◽  
Hyun Ju Kwon

2018 ◽  
Vol 19 (11) ◽  
pp. 3550 ◽  
Author(s):  
Eleonora Mungo ◽  
Loredana Bergandi ◽  
Iris Salaroglio ◽  
Sophie Doublier

Emerging evidence supports the idea that a dysfunction in cell metabolism could sustain a resistant phenotype in cancer cells. As the success of chemotherapeutic agents is often questioned by the occurrence of multidrug resistance (MDR), a multiple cross-resistance towards different anti-cancer drugs represent a major obstacle to cancer treatment. The present study has clarified the involvement of the carbon metabolites in a more aggressive tumor colon adenocarcinoma phenotype and in a chemoresistant mesothelioma, and the role of pyruvate treatment in the reversion of the potentially related resistance. For the first time, we have shown that human colon adenocarcinoma cells (HT29) and its chemoresistant counterpart (HT29-dx) displayed different carbon metabolism: HT29-dx cells had a higher glucose consumption compared to HT29 cells, whereas human malignant mesothelioma (HMM) cells showed a lower glucose consumption compared to HT29 cells, accompanied by a lower pyruvate production and, consequently, a higher production of lactate. When treated with pyruvate, both HT29-dx and HMM cells exhibited a re-established accumulation of doxorubicin and a lower survival ability, a decreased activity of multidrug resistance protein 1 (MRP1) and a restored mitochondrial respiratory chain function, improving the effectiveness of the chemotherapeutic agents in these resistant cancer cells.


Author(s):  
Fataneh Hashem-Dabaghian ◽  
Asie Shojaii ◽  
Jinous Asgarpanah ◽  
Maliheh Entezari

Objectives: Regarding the high prevalence of cancer in Iran and the cytotoxic properties of T. polium, the current study aimed to investigate the cytotoxic and anti-mutagenicity effect of T. polium essential oil (TpEO) on human colon adenocarcinoma cell line (HT29). Methods: HT29 cells were cultured in L-glutamine, RPMI Sigma (1640), with 10% of FBS (fetal bovine serum). Then, the cultures were incubated with 5% CO2 at 37°C, and MTT assay was used to recognize cell proliferation under the inhibitory influence of TpEO. The cell cycle progression was monitored by Sub-G1 apoptosis assay using flow cytometry. Eventually, the anti-mutagenicity property was evaluated using the Ames test employing TA100 and exposure to sodium azide as the carcinogenic substance. Results: The cytotoxic effect of TpEO on HT29 cells was 66.867 ± 1.37 µg/mL. Cultured HT29 cells treated with TpEO exhibited morphological features of apoptosis. TpEO preventive effect was about 78.18%. Conclusions: This study showed that TpEO may be useful for treating colon cancer.


Author(s):  
Sylvie Polak-Charcon ◽  
Yehuda Ben-Shaul

Human colon adenocarcinoma cell line HT29 was found to be a favorable system for the study of junctions assembly. Using scanning electron microscopy (SEM), thin sectioning (TEM) and freeze fracturing, we were able to demonstrate that HT29 cells grown to confluency have desmosomes but clearly lack tight or gap junctions. When treated with trypsin, cells were rounded up, made contacts, and within 15 min formed tight and gap junctions. The desmosomes, however, were split to hemi-desmosomes. These findings agree with results obtained for other experimental systems.In this work we have used cytochalasin B (CB), colchicine (C) and CB + C, drugs known to interfere with microfilaments and microtubules, in order to determine to what extent these structures are involved with the assembly of tight junctions in HT29 cells treated with trypsin. The drugs were added to confluent monolayered cells (CB:20 μg/ml - 1 h; C: 10-4 M - 3 h; CB:20 μg/ml + C: 10-4 M/ml - 3 h), then trypsin was added to a final concentration of 0. 25% for 15 min.


2008 ◽  
Vol 294 (2) ◽  
pp. C579-C590 ◽  
Author(s):  
Youssef Abdul Jalil ◽  
Vera Ritz ◽  
Ana Jakimenko ◽  
Christoph Schmitz-Salue ◽  
Heike Siebert ◽  
...  

The clarification of subcellular localization represents an important basis toward characterization of ATP-binding cassette (ABC) transporters and resolution of their roles in cellular physiology. Rat Abcb6 (rAbcb6) is a membrane-situated half-transporter belonging to the ABC protein superfamily. To investigate rAbcb6 subcellular distribution, the human colon adenocarcinoma line LoVo, which we found to be devoid of endogenous human ABCB6 mRNA, was employed for heterologous expression of rAbcb6 bearing a COOH-terminal epitope tag (rAbcb6-V5). Following subcellular fractionation, rAbcb6-V5 was observed as an N-glycosylated protein in fractions enriched with lysosomal/endosomal membrane proteins. Indirect immunofluorescence analyses of rAbcb6-V5 using antibodies against a rAbcb6-specific peptide or against the V5-tag revealed a punctate pattern that was colocalized with lysosome-associated membrane protein 1 (LAMP1), a marker of lysosomes/late endosomes. Substantial colocalization of tagged rAbcb6 with lysosomal/late endosomal marker was confirmed with living, unfixed LoVo cells coexpressing rAbcb6 fused to enhanced green fluorescent protein. Vesicular distribution in LoVo cells was consistent with localization of endogenous rAbcb6 expressed in rat primary hepatocyte cultures or in liver sections, as revealed by overlap of rat Lamp1 with rAbcb6 in double immunofluorescence analyses. Since several Abcb6-related half-transporters confer heavy metal tolerance, we investigated whether rAbcb6 expression in LoVo cells might affect sensitivity toward transition metal toxicity. Applying MTT viability assays, we found that expression of either rAbcb6-V5 or untagged rAbcb6 conferred tolerance toward copper, but not to cobalt or zinc. In summary, these results demonstrate that rAbcb6 is a glycosylated protein targeted to intracellular vesicular membranes and suggest involvement of rAbcb6 in transition metal homeostasis.


2006 ◽  
Vol 241 (2) ◽  
pp. 228-234 ◽  
Author(s):  
Hideki Arimochi ◽  
Kyoji Morita ◽  
Keiko Kataoka ◽  
Shusuke Nakanishi ◽  
Tomomi Kuwahara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document